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Background and aims: In liver cirrhosis, disruption of the intestinal barrier facilitates bacterial
translocation and spontaneous bacterial peritonitis. Insulin-like growth factor I (IGF-I) is an anabolic
hormone synthesised by hepatocytes that displays hepatoprotective activities and trophic effects on the
intestine. The aim of this study was to investigate the effect of IGF-I on intestinal barrier function in cirrhotic
rats.
Methods: In rats with carbon tetrachloride induced cirrhosis, we investigated the effect of IGF-I therapy on:
(a) portal pressure; (b) intestinal histology and permeability to endotoxin and bacteria; (c) intestinal
expression of cyclooxygenase 2 (COX-2) and tumour necrosis factor a (TNF-a), two factors that influence
in a positive and negative manner, respectively, the integrity of the intestinal barrier; (d) intestinal
permeability to 3H-mannitol in rats with bile duct ligation (BDL); and (e) transepithelial electrical resistance
(TER) of polarised monolayers of rat small intestine epithelial cells.
Results: IGF-I therapy reduced liver collagen expression and portal pressure in cirrhotic rats, induced
improvement in intestinal histology, and caused a reduction in bacterial translocation and endotoxaemia.
These changes were associated with diminished TNF-a expression and elevated COX-2 levels in the
intestine. IGF-I reduced intestinal permeability in BDL rats and enhanced barrier function of the monolayers
of epithelial intestinal cells where lipopolysaccharide (LPS) caused a decrease in TER that was reversed by
IGF-I. This effect of IGF-I was associated with upregulation of COX-2 in LPS treated enterocytes.
Conclusions: IGF-I enhances intestinal barrier function and reduces endotoxaemia and bacterial
translocation in cirrhotic rats. IGF-I therapy might be useful in the prevention of spontaneous bacterial
peritonitis in liver cirrhosis.
I
n liver cirrhosis, portal hypertension, malnutrition, and
poor liver function cause trophic changes in the intestine
and disruption of intestinal barrier function (IBF) by
mechanisms not fully understood.1 2 As a result, there is
increased permeability of the intestinal wall to enteric
bacteria leading to endotoxaemia and septic complications,
such as spontaneous bacterial peritonitis (SBP).3 Bacterial
translocation across the bowel wall induces tumour necrosis
factor a (TNF-a) production which in turn decreases IBF and
increases bacterial translocation.4 5 Endotoxaemia resulting
from bacterial translocation may adversely affect liver
function and may contribute to the systemic haemodynamic
derangement of liver cirrhosis.6 Therefore, restoring the
integrity of the intestinal barrier is an important goal in the
management of liver cirrhosis.
Insulin-like growth factor I (IGF-I) is produced in different
tissues following growth hormone (GH) stimulation, with
the liver being the major source of the circulating hormone.7 8
IGF-I exerts potent anabolic and trophic effects in many
tissues acting in an endocrine, paracrine, and autocrine
manner.9 Levels of IGF-I are markedly decreased in liver
cirrhosis,10 and previous data from our laboratory have shown
that IGF-I therapy reduces liver fibrosis,11 improves liver
function,12 increases intestinal absorption of nutrients,13–15
and corrects osteopenia16 and hypogonadism in experimental
liver cirrhosis.17
It has been reported that IGF-I enhances the growth of the
intestinal mucosa after intestinal resection or severe burns18 19
and stimulates proliferation of different cell lines derived
from the intestinal epithelium.20 As the intestine is particu-
larly rich in IGF-I receptors,21 we have postulated that IGF-I
deficiency might contribute to derangement of IBF in liver
cirrhosis. In the present work, we investigated whether IGF-I
could improve intestinal histology and reduce bacterial
translocation and endotoxaemia in cirrhotic rats. Moreover,
we analysed whether a short course of IGF-I therapy could
decrease intestinal permeability in rats with bile duct ligation
(BDL) (another model of disrupted IBF),22 and whether IGF-I
could enhance the barrier function of monolayers of isolated
rat intestinal epithelial cells. As it has been demonstrated
that TNF-a disrupts the integrity of the intestinal barrier and
cyclooxygenase 2 (COX-2) derived prostaglandins exert a
protective effect on IBF,23 24 we analysed the influence of
IGF-I on intestinal expression of TNF-a and COX-2. Our
findings indicate a potential therapeutic value of this
hormone in the prevention of bacterial translocation in liver
cirrhosis.25
METHODS
Animal models
The study was conducted in agreement with the guidelines
for animal research, according to the Guide for the Care and
Use of Laboratory Animals, and was approved by the Ethical
Abbreviations: BDL, bile duct ligation; Cola1, procollagen a1(I); GH,
growth hormone; IBF, intestinal barrier function; IGF-I, insulin-like
growth factor type I; PHE, portal hypertensive enteropathy; SBP,
spontaneous bacterial peritonitis; TER, transepithelial electrical
resistance; COX-2, cyclooxygenase 2; TNF-a, tumour necrosis factor a;
LPS, lipopolysaccharide; CCl4, carbon tetrachloride; DMEM, Dulbecco’s
modified Eagle’s medium; FBS, fetal bovine serum; RT-PCR, reverse
transcription-polymerase chain reaction
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and Research Committee of the Germans Trias i Pujol
University Hospital.
Induction of cirrhosis by carbon tetrachloride
administration
Male Sprague-Dawley rats weighing 100–110 g were caged
individually at a constant room temperature of 21 C˚ and a
17/7 hour light/dark cycle. Animals were fed 20–25 g/day of
standard rat chow (A04; Panlab SA, Barcelona, Spain) and
received 1.5 mmol/l phenobarbital (Luminal; Bayer,
Leverkusen, Germany) in drinking water. Cirrhosis was
induced in 30 rats by gavage of carbon tetrachloride (CCl4)
using an orogastric feeding tube (Popper and Sons; New
Hyde Park, New York, USA) without general anaesthesia, as
described previously,26 to complete eight weeks of CCl4
administration. After eight weeks of CCl4 administration,
animals (15 in each group) were randomised to subcuta-
neous treatment with recombinant human IGF-I (Chiron
Corporation, Emeryville, California, USA) (2 mg/100g body
weight/in two divided doses) (CI-IGF group) or vehicle (CI
group) for 21 days. Ten healthy rats receiving vehicle were
analysed in parallel.
On days 0 and 21 after the beginning of treatment, animals
were weighted and plasma was collected and stored at 280 C˚
until use. At the end of the treatment period, animals
underwent laparotomy for measurement of portal pressure,
as well as collection of blood and tissue samples, and then the
animals were sacrificed. A tissue sample from the left major
liver lobe and one from the ileum, previously washed with
phosphate buffered saline (BioMe´rieux SA, Marcy l’Etoile,
France), was processed (fixed in Bouins solution) for
histological examination. Tissue specimens were immediately
frozen by immersion in liquid nitrogen and stored at 280 C˚.
Blood samples were used for determination of biochemical
parameters and levels of IGF-I.
Bile duct l igation (BDL) model
Three groups of rats weighing 200–220 g were anaesthetised
by isoflurane inhalation (n = 3, each). After a 3 cm abdom-
inal midline incision, the common bile duct was isolated,
double ligated with a 3–0 silk suture, and transected between
ligatures. In sham operated rats (n = 3), the same operation
was performed but neither ligatures nor bile duct section
were carried out. The day after surgery, treatments were
started: one group of BDL rats received subcutaneous
administration of recombinant human IGF-I (Chiron
Corporation) (2 mg/100 g body weight/in two divided doses)
over nine days (BDL-IGF-I group) whereas sham operated
and control BDL rats received two subcutaneous injections of
equivalent volumes of vehicle. At day 10 after surgery, in vivo
intestinal permeability was determined as described below.
Cell culture
Rat small intestine epithelial cells (IEC–6), which are known
to posses IGF-I receptors,27 were purchased from American
Type Culture Collection (Rockville, Maryland, USA). Cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal bovine serum (FBS), together with
100 mg streptomycin and 60 mg penicillin per litre of growth
medium and used for the experiments as monolayers at 37 C˚
in 5% CO2.
Analytical methods
Liver function tests were determined by routine laboratory
methods using an Autoanalyser DAX-48 (Toshiba
Corporation, Nasu Works, Shimuishigami, Japan). Plasma
IGF-I levels were measured by enzyme immunoassay (DSL-
10-2900 Active Rat IGF-I; DSL, Webster, Texas, USA) and
results are expressed in ng/ml.
Assessment of histopathological changes
Liver histopathological changes were assessed in haematox-
ylin-eosin stained sections, and Masson’s trichrome stainings
were used to verify the degree of fibrosis. In the ileum,
assessment of histopathological alterations was based on
evaluation of villous atrophy, submucosal oedema, and ileal
lymphangiectasias. The degree of villous atrophy was scored
as follows: 1, absent; 2, mild; 3, moderate; and 4, severe.
Portal pressure determination
At laparotomy, portal pressure was measured by direct
intraportal insertion of a small polyethylene catheter
(Abbocath-T 20G, ø 1.1 mm, L 32 mm; Abbott, Sligo,
Ireland), connected to a Lectromed High Gain Preamplifier
type 5240 (Lectromed, Letchworth, UK). Results are
expressed as mm Hg.
Assessment of bacterial translocation
At the end of the treatment period, animals underwent
laparotomy in an unfasted state. The operation was
performed under general anaesthesia (subcutaneous keta-
mine, atropine, and diazepam) and strict aseptic conditions.
At laparotomy, potential sources of secondary peritonitis
were carefully sought. Samples for culture were harvested in
the following order: portal venous blood, systemic venous
blood (inferior vena cava) (2 ml of each), and three
mesenteric lymph nodes (particularly those draining lymph
from the ileum and caecum). A section of liver and ileum
were obtained for histology.
Blood samples were cultured by immediate inoculation
into blood culture bottles (FAN; Organon Teknika Corp,
Durham, North Carolina, USA). Mesenteric lymph nodes
were washed free of blood with sterile saline solutions, and
immediately homogenised in brain-heart medium. Aliquots
were also plated on blood agar and MacConkey agar plates
for qualitative and quantitative studies.
Plasma endotoxin levels
Endotoxin quantification was carried out with a Kinetic-
colorimetric Limulus Amebocyte Lysate test (Endosafe
Endochrome-K; Charles River, Lyon, France) in samples of
cirrhotic rats and healthy animals. Briefly, plasma samples
were collected in pyrogen-free tubes, diluted 1/10 with sterile
normal saline, heated at a temperature of 75 C˚ for five
minutes in a water bath, and then diluted again five times
with sterile normal saline to obtain a final dilution of 1:50
(vol:vol). Aliquots (100 ml) were transferred under aseptic
conditions to a 100 well microplate. Then, the Limulus
amoebocyte lysis reagent (100 ml) was added to each well.
The kinetics of cytolysis were determined to permit calcula-
tion of endotoxin concentration (EU/ml).28
Western blotting
COX-2 expression was determined in intestinal and IEC-6 cell
protein lysates that were obtained as follows. Intestinal tissue
(5 mg) of each sample were homogenised in a lysis buffer
(50 mmol/l Tris-HCl, 0.1 mM EGTA, 0.1 mM EDTA, 2 mmol/l
leupeptin, 1 mmol/l phenylmethylsulfonyl fluoride, 1% (v/v)
Nonidet P-40, 0.1% sodium dodecyl sulphate, and 0.1%
deoxycholic acid; pH = 7.5) for one hour at 4 C˚. Lysate was
centrifugated for 10 minutes at 3000 g and supernatant was
ultracentrifuged at 100 000 g for one hour. Samples were
purified with Streptococcus G protein and sepharose, and
protein quantification of supernatant samples was performed
using the Bradford assay.
IEC–6 cells were grown in 60 mm dishes to 50–70%
confluence and then switched to DMEM medium (Gibco–
BRL, Invitrogen, Barcelona, Spain) without serum. Cells were
homogenised according to the following protocol: cells were
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washed twice with phosphate buffered saline buffer and
resuspended in 1 ml of lysis buffer (phosphate buffered
saline pH 7.4, 0.1% Nonidet P40, complete protease inhibitor
cocktail, and 50 mM NaF). Lysates were centrifuged
(15 000 g, 30 minutes, 4 C˚) and the supernatant (crude
extract) was quantified for total protein content using the
Bio-Rad protein assay (Bio-Rad Laboratories, Hercules,
California, USA).
Protein lysates were separated by sodium dodecyl sul-
phate-polyacrylamide gel electrophoresis on 12% polyacryla-
mide gel (for resolutive zone) and 30% polyacrylamide (for
carrier zone), and proteins were electroblotted on nitrocellu-
lose membranes (Protran, Schleicher and Schuell, Dassel,
Germany) over 45 minutes at 120 volts. Membranes were
washed in Tris buffered saline and blocked with 5% milk in
TTBS (Tris-HCl 20 mM, NaCl 140 mM and Tween 20 0.05%)
and incubated with first antibody for one hour and then with
second peroxidase conjugated antibody for one hour.
Antibodies were from Santa Cruz Biotechnology (Santa
Cruz, California, USA). Equal loading was demonstrated
with an antiactin polyclonal antibody (Calbiochem, Bad
Soden, Germany).
RNA isolation and quantitative PCR
Real time reverse transcription-polymerase chain reaction
(RT-PCR) was performed to quantify expression of the
mRNAs of procollagen a1(I) (Cola1), TNF-a and b-actin
(table 1). For real-time quantitative RT-PCR, reverse tran-
scription of total liver RNA to cDNA was performed at 42 C˚
for one hour using random primers (Boehringer Ingelheim,
Ingelheim, Germany) and RTase (Gibco). During PCR
amplification, cDNA was incubated with a mix containing
SYBR Green I, a dye specific for double stranded DNA
(LightCycler-FastStart DNA Master SYBR Green I; Roche
Diagnostics, Barcelona, Spain). Amplification conditions
using a thermocycler (LightCycler; Roche Molecular
Biochemicals, Barcelona, Spain) were one step denaturation
for 10 minutes at 95 C˚, followed by multiple cycles of
denaturation for 15 seconds at 95 C˚, annealing for five
seconds at 61 C˚, and extension for 13 seconds at 72 C˚. The
number of cycles was 35, 40, and 35, for Cola1, TNF-a, and
b-actin, respectively. Specification of each PCR product was
established based on its melting temperatures (LightCycler
software version 3.39; Roche Molecular Biochemicals), and
appropriate size was verified on agarose gels. To prepare
standards, PCR generated fragments were isolated from
agarose gels, purified (GeneClean II; Q-Biogene, Irvine,
California, USA), cloned into the pGEM T-Easy vector
(Promega, Madison, Wisconsin, USA) and sequenced (ABI
PRISM 310 Genetic Analyzer; Perkin Elmer, Wellesley,
Massachusetts, USA). Standard curves were generated from
serial dilutions of control linearised plasmids to obtain
relative quantitation. Quantification was represented as
expression units (that is, 2ˆCT*10000, where CT is the
difference in number of cycles between b-actin expression
and that of the measured gene).
Measurement of intestinal permeabili ty in vivo
Intestinal permeability was evaluated in a BDL model by
measuring intestinal absorption of 3H-mannitol (Perkin
Elmer, Boston, USA). Briefly, 10 days after BDL or sham
operation, an abdominal incision was performed to expose a
jejunal loop of approximately 15 cm long. Both ends of the
loop were cannulated to recirculate (2 ml/min) a modified
Krebs-Henseleit buffer (122 mM NaCl, 3.5 mM KCl, 25 mM
NaHCO3, 1.2 mM KH2PO4 (pH 7.5)) with 1 Ci/ml of
3H-mannitol and 1 mM of cold mannitol for 30 minutes.
Samples of perfusion medium were collected every 10 min-
utes for counting radioactivity in a Beckman LS 6500
scintillation counter (Beckman, Fullerton, USA). At the end
of the experiment the intestinal loop was extracted,
weighted, and dried in a drying oven at 65 C˚. Intestinal
permeability was estimated as the difference between total
radioactivity present in the recirculation medium before and
after the experiment, divided by the dry weight of the
intestine.
Measurement of transepithelial electrical resistance
Transepithelial electrical resistance (TER) was used to
monitor the integrity of the barrier function of confluent
polarised monolayers of IEC-6. A higher TER reflects stronger
tight junctions between cells and decreased monolayer
permeability. Transwells (6.5 mm diameter, 0.4 mm pore
size; Costar, Cambridge, Massachusetts, USA) were seeded
with 106106 epithelial cells per well in DMEM and 10% FBS
and placed in 24 multiwell plates. Confluence of IEC–6 was
usually reached within seven days. Twenty hours before
stimulation, cells were equilibrated with fresh medium with
an apical and basolateral volume of 2 ml in each chamber.
IGF-I (100 ng/ml) and lipopolysaccharide (LPS 0.4 mg/ml)
were added to basolateral and apical chambers, respectively.
Each experiment was performed in triplicate. TER measure-
ments were made using a Millicell Electrical Resistance
System (Millipore, Bedford, Massachusetts, USA). To calcu-
late the TER of each cell monolayer, the mean value of
transwells without cells was subtracted from the monolayer
measurements and corrected for the area of the transwell
(0.33 cm2).
Statistical analysis
Results are expressed as mean (SEM). Comparisons of
quantitative variables among groups were made using one
way ANOVA or its corresponding non-parametric (Kruskal-
Wallis) test, as required. Post hoc comparisons were
performed with the Duncan or Mann-Whitney non-para-
metric tests. The x2 test was used for comparisons of
percentages. Intergroup variations of quantitative and qua-
litative variables were assessed by the paired Student t test
and McNemar’s test, respectively. A p value ,0.05 was
considered to be significant.
RESULTS
IGF-I, l iver damage, and portal pressure
At baseline, plasma IGF-I concentration was similar in the
three groups of animals (1283.5 (89.1); 1387.2 (97.7), and
1188.5 (179.6) ng/ml in CI-IGF, CI, and normal rats,
respectively; NS). At the end of the experimental period,
administration of human IGF-I caused, as expected, a
decrease in levels of endogenous IGF-I in treated rats
resulting from feedback inhibition of GH synthesis by
exogenously administered hormone (571.09 (47.7) v
1285.23 (130.6) ng/ml in CI-IGF and CI, respectively;
p,0.05).
In agreement with our previous observations,29 CI-IGF
animals showed a rate of weight gain significantly higher
than that observed in the CI group (22.9 (1.5)% and 14.85
Table 1 Oligonucleotide sequences used in reverse
transcription-polymerase chain reactions
Cola1(I) Sense 59-GCA AAG AGT AGT CTA CAT GTC TAG-39
Antisense 59-CCT ACA TCT TCT GAG TTT GG-39
TNF-a Sense 59-GAG TGA CAA GCC TGT AGC CC-39
Antisense 59-CCC TTC TCC AGC TGG AAG AC-39
b-actin Sense 59-GTG ACG AGG CCC AGA GCA AGA G-39
Antisense 59-AGG GGC CGG ACT CAT CGT-39
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(1.1)%, respectively; p,0.01). Also, levels of Cola1 mRNA
were significantly decreased in CI-IGF rats compared with CI
animals (3814 (523); 7420 (1697), and 2089 (637) expression
units in CI-IGF, CI, and normal rats, respectively; p,0.05).
Reduced hepatic fibrogenesis in CI-IGF rats was consistent
with our previous data12 29 and was associated with lower
inflammatory activity in the liver, as reflected by decreased
TNF-a mRNA levels in this group compared with CI animals
(92.4 (10.5), 158.6 (28.8), and 93.0 (15.6) expression units in
CI-IGF, CI, and normal rats, respectively; p,0.05). The value
of portal pressure was 5.2 (0.4) mm Hg in normal rats and
reached values of 11.6 (0.6) mm Hg in untreated cirrhotic
animals. In CI-IGF rats, portal pressure was significantly
lower (6.4 (0.7) mm Hg; p,0.01) than in CI rats.
I leal histopathology and expression of TNF-a and
COX-2 in the intestine
In cirrhotic rats, ileal structure was altered by the presence of
villous atrophy, lymphangiectasias, and submucosal oedema.
These changes most probably reflect the intestinal distur-
bance associated with liver cirrhosis and portal hypertension
and not any injurious effect of CCl4 on the intestine as the
toxin was stopped three weeks before sacrificing the animals.
The degree of villous atrophy was slightly but significantly
lower in CI-IGF rats than in the CI group (2.13 (0.35) v 2.60
(0.50); p,0.01). Submucosal oedema was not found in
CI-IGF rats while it was noticeable in CI animals.
Lymphangiectasias were also less prominent in the CI-IGF
group than in untreated cirrhotic rats (fig 1). The improve-
ment in ileal histopathology observed in CI-IGF rats was
associated with significant changes in TNF-a and COX-2
expression in the intestinal wall. As shown in fig 2A, TNF-a
mRNA was intensely upregulated in untreated cirrhotic rats
compared with normal animals while CI-IGF animals
showed values comparable with healthy controls.
Interestingly, in contrast with TNF-a, levels of COX-2 protein
were markedly reduced in the CI group compared with
healthy animals. COX-2 increased to values comparable to
normal in cirrhotic rats that received IGF-I therapy (fig 2B).
Bacterial translocation and plasma endotoxin levels
Bacterial translocation to mesenteric lymph nodes was not
detected in healthy animals while it occurred in 10 of 15 CI
animals (66.6%). In rats from the CI-IGF group, bacterial
translocation was found in only four of 15 rats (26.6%). The
difference between CI and CI-IGF was statistically significant
(p,0.001) (fig 3). The organisms isolated from mesenteric
lymph nodes were all aerobes of enteric origin. Escherichia coli
was the most frequent Gram negative bacteria that was
translocated (table 2).
The lower prevalence of bacterial translocation in CI-IGF
rats was associated with reduced plasma endotoxin levels in
this group compared with group CI (0.949 (0.020) v 1.102
(0.083) EU/ml; p,0.05). Plasma endotoxin values in CI-IGF
rats were comparable with those found in healthy controls
(0.934 (0.026) EU/ml) (fig 3).
Figure 1 Ileal histology in the three experimental groups of animals. HR, healthy rats; CI, cirrhotic rats who received placebo; and CI-IGF, cirrhotic
rats treated with insulin-like growth factor type I. Arrows show lymphangiectasias and submucosal oedema, which were more prominent in the CI
group.
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Effect of IGF-I on intestinal permeability in vivo
To further analyse the effect of IGF-I on IBF in vivo, we
measured intestinal permeability to 3H-mannitol in BDL rats
treated with either IGF-I or vehicle for nine days. Figure 4
shows that BDL produces a significant increase in intestinal
permeability to 3H-mannitol compared with the sham
operated group. In contrast, in BDL rats treated with IGF-I,
intestinal permeability was significantly lower than in non-
treated BDL rats, and similar to that observed in sham
operated rats (fig 4).
Effect of LPS and IGF-I on transepithelial electrical
resistance and COX-2 expression in monolayers of rat
enterocytes
We then determined whether enhancement of IBF by IGF-I
could involve a direct effect of this hormone on the intestinal
epithelial cell layer. To this aim rat small intestine epithelial
IEC-6 cells were cultured as confluent polarised monolayers
in transwell bicameral chambers and TER was measured as a
reflection of monolayer integrity. A higher TER indicates
stronger tight junctions between cells and decreased mono-
layer permeability. As LPS has been implicated in disruption
of epithelial barrier integrity in different pathological condi-
tions,30–33 including liver cirrhosis,34 we examined whether
IGF-I might counteract the effect of LPS on barrier function
of IEC-6 monolayers.
After incubation of cells with apical LPS for 24 hours, we
observed that TER decreased by approximately 50% with
respect to control values (p,0.05) (fig 5A). In contrast,
incubation with basolateral IGF-I for the same period of time
caused an approximate 50% increase in TER (p,0.05).
Interestingly, cells that were simultaneously incubated with
IGF-I (basolateral) and LPS (apical) showed values of TER
slightly above control, indicating that IGF-I was able to
completely reverse the disruption of epithelial barrier func-
tion induced by LPS.
As COX-2 displays strong protective effects on the gut
epithelial barrier,24 35 36 we tested whether LPS and/or IGF-I
might influence COX-2 protein levels in cultured IEC-6 cells.
We found that incubation of IEC-6 cells for six hours with
IGF-I or LPS alone induced little change in COX-2 expression
while the combination of IGF-I and LPS resulted in notice-
able COX-2 upregulation, suggesting that this may be a
mechanism by which IGF-I may counteract the deleterious
effect of LPS on epithelial barrier function (fig 5B).
DISCUSSION
We have previously shown that IGF-I displays anabolic and
hepatoprotective effects in rats with experimental liver
cirrhosis.12–15 37 In agreement with these data, in our present
work we found a greater increase in weight gain and reduced
TNF-a and Cola1 expression in liver tissue in cirrhotic rats
that received IGF-I treatment. Moreover, CI-IGF animals
exhibited a significant decrease in portal pressure compared
with control cirrhotic rats, probably because of attenuated
fibrogenesis and reduced hepatic production of proinflam-
matory mediators that may increase intrahepatic vascular
resistances.38 39
This study showed that intestinal histopathological
changes are improved by administration of IGF-I to cirrhotic
rats. Thus partial villous atrophy, submucosal oedema and
lymphangiectasias present in CI animals were partially
prevented by therapy with IGF-I. In parallel with these
findings, we observed that bacterial translocation and
Table 2 Bacterial species isolated from mesenteric
lymph nodes of cirrhotic rats with bacterial translocation
Bacterial species
No of positive
cases
CI Escherichia coli 10
CI-IGF Escherichia coli 2
Enterococcus sp 1
Streptococcus viridans 1
CI, cirrhotic rats treated with vehicle (n = 15); CI-IGF, cirrhotic rats treated
with insulin-like growth factor type I (n = 15).
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Figure 4 Intestinal permeability to 3H-mannitol in the intestine of sham
operated rats, bile duct ligated rats (control BDL), and bile duct ligated
rats treated with insulin-like growth factor type I (BDL-IGF-I). An
abdominal incision was performed in animals to expose a jejunal loop of
approximately 15 cm long. Both ends of the loop were cannulated to
recirculate (2 ml/min) medium containing 1 mCi/ml of 3H-mannitol and
1 mM of cold mannitol for 30 minutes. Values represent the difference
between total radioactivity present in the recirculation medium before
and at the end of the experiment, divided by the dry weight of the
intestine (see methods). Bars show mean (SEM) of three individual
experiments in each group. *p,0.05 versus the other groups.
Control
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
1.60
1.80
Tr
a
n
se
p
it
h
e
lia
l
e
le
ct
ri
ca
l
re
si
st
a
n
ce
(f
o
ld
va
ri
a
ti
o
n
v
co
n
tr
o
l)
A
B
COX-2
Actin
IGF-I LPS LPS
+
IGF-I
Control IGF-I LPS LPS
+
IGF-I
*
*

Figure 5 (A) Transepithelial electrical resistance in control rat intestinal
epithelial cells (IEC-6), and after treatment with insulin-like growth factor
type I (IGF-I), lipopolysaccharide (LPS), or LPS plus IGF-I. Bars represent
mean (SEM) of at least three individual experiments. *p,0.05 versus
control cells; p,0.05 versus LPS treated cells. (B) Western blot analysis
of cyclooxygenase 2 (COX-2) protein expression by IEC-6 cells treated
as mentioned in (A). Actin expression is shown as a protein loading
control.
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endotoxaemia were significantly reduced in animals that
received IGF-I treatment. These favourable effects of IGF-I on
the intestine can be explained in part by reduction of portal
pressure observed in CI-IGF rats but also by direct protection
of the integrity of the mucosal barrier.
Here we showed that altered IBF in liver cirrhosis is
associated with upregulation of TNF-a in the intestinal wall.
It seems possible that enhanced TNF-a expression in the gut
of cirrhotic rats may result from increased intestinal
leakiness, allowing penetration of bacteria and endotoxin
into the gut wall. In this context, the reduction in intestinal
TNF-a levels observed in CI-IGF rats might reflect improve-
ment of IBF. However, TNF-a is similarly downregulated in
the liver of these animals and we also found that IGF-I
attenuates TNF-a production in response to endotoxin in a
macrophage cell line (data not shown). These observations
suggest that IGF-I may display a direct anti-inflammatory
activity in the gut that contributes to the protection of IBF. In
this respect it has been shown that increased production of
TNF-a in the intestine is a critical event leading to loss of IBF
and bacterial translocation,4 5 40 and that anti-TNF-a thera-
pies may prevent bacterial translocation and SBP.41
Interestingly, we observed that intestinal expression of
COX-2, a mediator of the synthesis of protective prostaglan-
dins in the gut, was reduced in CI animals. To our knowledge,
the role of defective COX-2 expression in the disruption of
intestinal barrier in liver cirrhosis has not been investigated
previously. Our data suggest that impaired COX-2 expression
may contribute to the derangement of IBF in cirrhotic
animals as IGF-I treatment leads to improvement in IBF in
parallel with recovery of intestinal COX-2 expression.
Enhancement of COX-2 expression in the intestine is in
agreement with the reported ability of IGF-I to upregulate
this enzyme and prostaglandin synthesis in colon cancer
cells.42
To see whether the benefit of IGF-I on IBF of cirrhotic rats
was due not only to a reduction in portal pressure but also to
a trophic effect on the intestine, we analysed whether our
IGF-I therapeutic regimen given for a short period of time
could influence intestinal permeability in a more acute model
of impaired intestinal barrier, as is the case of rats with BDL.22
By measuring intestinal permeability to 3H-mannitol in BDL
rats, we demonstrated that IGF-I given for a few days
markedly improved IBF, suggesting a direct protective effect
of the hormone on the intestinal wall. This concept is in
agreement with data in the literature showing that IGF-I
given for only five days to rats with severe burns increased
mucosal DNA and protein content and reduced the incidence
of bacterial translocation to the mesenteric lymph node from
89% in the placebo group to 30% in the treated group.19 Thus
it appears that the improvement in IBF observed in cirrhotic
rats treated with IGF-I may depend on both the reduction in
portal pressure and direct trophic effects on the gut wall.
In order to investigate whether IGF-I might act directly on
enterocytes to increase IBF, we performed in vitro studies
with cells of the rat small intestine (IEC-6 cells). We found
that IGF-I not only increased the barrier function of the
epithelial monolayer (as assessed by TER), but was also able
to revert the deleterious effect of LPS on TER. Moreover,
we found that cultured IEC-6 cells increased production of
COX-2 on LPS exposure when IGF-I was added to the
incubation medium, indicating that this hormone was able to
enhance defensive mechanisms in intestinal epithelial cells
when challenged with bacterial endotoxin. These findings are
relevant to the pathophysiology of liver cirrhosis as LPS has
been shown to be implicated in the disruption of epithelial
barrier integrity in this condition.34
IGF-I has been proposed as a promising therapy for
cirrhotic patients on the basis of preclinical data showing
that this hormone displays hepatoprotective and antifibro-
genic activities in vivo.11 12 Data from a recent, double blind,
randomised, clinical trial of IGF-I versus placebo in patients
with alcoholic cirrhosis showed that this therapy is well
tolerated and was associated with a significant increase in
albumin levels during the treatment period.43 However, in
this trial, few patients with advanced cirrhosis were included
and the effect of the therapy on bacterial translocation was
not addressed.
In cirrhotic patients bacterial translocation has severe
pathophysiological consequences. In addition to SBP and
other septic complications leading to renal and multiorgan
dysfunction, bacterial invasion may alter platelet function
and may contribute to an increase in portal pressure by
promoting splanchnic vasodilation in the bowel and by
inducing the synthesis of endothelin and proinflammatory
mediators in the liver, thus increasing the risk of variceal
bleeding.42 44 IGF-I might therefore be an attractive therapy
not only because of its hepatoprotective properties but also
because of its trophic effect on the intestine that defends
against bacterial translocation.
In conclusion, our data indicate that IGF-I therapy
prevents the development of portal congestive enteropathy
and the occurrence of bacterial translocation in experimental
cirrhosis. Clinical trials are needed to determine whether this
hormone might favourably influence the natural history of
liver cirrhosis and reduce the risk of SBP and other septic
complications in cirrhotic patients.
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